Comparative Pharmacology
Head-to-head clinical analysis: ESOMEPRAZOLE STRONTIUM versus FLUXID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESOMEPRAZOLE STRONTIUM versus FLUXID.
ESOMEPRAZOLE STRONTIUM vs FLUXID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor that inhibits the H+/K+ ATPase in gastric parietal cells, suppressing gastric acid secretion.
FLUXID is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity by blocking the reuptake of serotonin at the presynaptic neuronal membrane, increasing serotonin availability in the synaptic cleft.
40 mg orally once daily; for healing of erosive esophagitis, 40 mg orally once daily for 4-8 weeks; for maintenance of healing of erosive esophagitis, 20 mg orally once daily; for GERD, 20 mg orally once daily; for Helicobacter pylori eradication, 40 mg orally twice daily for 10 days in combination with antibiotics.
1-2 g IV every 8 hours; maximum 6 g/day.
None Documented
None Documented
Terminal elimination half-life: 1.0–1.5 hours in healthy subjects; prolonged in poor CYP2C19 metabolizers (up to 3.5 hours).
Terminal half-life: 12 hours (range 10–14 hours). In renal impairment (CrCl <30 mL/min), half-life prolonged to 24–36 hours; dose adjustment required.
Primarily hepatic metabolism via CYP2C19 and CYP3A4. Approximately 80% of metabolites are excreted in urine and 20% in feces via bile. Less than 1% excreted unchanged.
Renal: 70% unchanged; Fecal: 20%; Biliary: 10%.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor